Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Phase 3 Trial Of LPCN 1154 In Postpartum Depression
Benzinga Newsdesk 11 months ago
BiotechNewsGeneral
Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as plannedMore than half of planned participants have completed dosing with no dose reductions,
- Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, study to continue as planned
- More than half of planned participants have completed dosing with no dose reductions, discontinuations, drug-related SAEs, loss of consciousness, or excessive sedation reported
- Topline results are on track for the second quarter of 2026